Key Takeaways
- Growth accelerates, guidance raised: Constant-currency revenue grew 10.6% YoY and the full-year organic CC growth guide was lifted to 13–14%, with acquisitions taking it to 14.5–15.5%.
- Margins expand for the fifth straight quarter: EBIT margin hit 11.9%, up 80 bps over four quarters, and the FY26 margin guide was raised to 11.5–12%. A ₹91.4 crore one-time gratuity charge under the new Labour Code was absorbed in the quarter.
- The large-deal engine is now repeatable: 13 large deals won in nine months, nearly double FY24’s full-year tally, with six from new logos. The pipeline stayed above US$1 bn despite strong closure.
- A deliberate onshore-to-nearshore rotation is underway: UK onshore headcount fell ~40% over four quarters while South Africa rose ~50%, creating revenue deflation but a structural margin tailwind that management is actively driving.
- What to watch next quarter: Whether the healthcare provider account rationalization’s optical growth drag materialises as flagged, the pace of TeleMedik integration, and any macro spillover from CMS final Medicare Advantage rates.
Revenue Growth & Guidance
- Broad-based momentum: Q3 revenue of ₹2,440 crore grew 16.2% YoY in rupee terms and 10.6% in constant currency, with all four verticals contributing. The Diverse Portfolio segment led at 21% YoY, helped by Pastdue Credit consolidation and retail expansion.
- Organic guidance raised: Management now expects 13–14% CC growth ex-acquisitions for FY26, up from prior expectations, with the lower end backed by clear line of sight and the upper end dependent on pipeline conversion. Including Pastdue Credit and TeleMedik, the range rises to 14.5–15.5%.
- Q4 sequential improvement expected: Growth is expected to step up QoQ in Q4, consistent with the upward trajectory through FY26. The guidance does not assume any macro impact.
- Client concentration falling: Revenue share of the Top 5 and Top 10 clients dropped 8% and 11% respectively over eight quarters, even as those top clients continued growing at the industry rate. Non-top-10 accounts are growing faster, fuelled by large deals.
- Non-linear revenue now dominant: Upwards of 50% of the business is non-linear in construct, and management plans to disclose more detail on outcome-based commercial structures from next fiscal year.
Idnani: "We have won 13 large deals in the first nine months of FY26, versus 14 wins in the entire FY25 and close to double the number of wins in FY24. Not just that, while previously our large deals almost always came from existing clients, six of the large deals this year so far came from new logos versus 5 in FY25."
Margin Trajectory & the Nearshore Pivot
- Fifth straight quarter of expansion: EBIT margin of 11.9% expanded 40 bps QoQ and 80 bps over the last four quarters, exceeding the stated annual objective of 50–75 bps. The FY26 margin guide was raised to 11.5–12%.
- One-time charge absorbed: A ₹91.4 crore charge for increased gratuity and leave encashment provisioning under the new Indian Labour Code, plus an ₹8.8 crore exceptional item for a legacy investment write-down, were both taken in the quarter without derailing the margin walk.
- The nearshore trade: UK onshore headcount fell ~40% over four quarters while South Africa headcount rose ~50%. This shifts work from high-cost/high-revenue to low-cost/low-revenue geographies, creating optical revenue deflation but a structural margin tailwind. 80% of gross hiring continues to go offshore or nearshore.
- Long-term margin path intact: Management reiterated the 50–75 bps annual expansion target through FY28, aiming for a 14–15% EBIT band over the next 3–4 years.
- Account rationalisation brought forward: Low-margin, low-growth tail accounts in the healthcare provider segment are being trimmed now, coinciding with new leadership. The drag on optical growth will persist for 2–3 quarters but supports medium-term margin aspirations.
Idnani: "Our UK onshore headcount has come down by about 40% over the last four quarters, while the corresponding headcount in South Africa during the same period is up by about 50%."
Vertical & Geographic Performance
| Vertical / Geography | Trend | Commentary |
|---|---|---|
| BFSI | ▲ 9% YoY | Clients prioritising regulatory adherence, CX and cost efficiency; mortgage transformation offerings resonating amid high rates; pipeline among strongest in recent quarters with at least one large deal in advanced closure. |
| Healthcare | ▲ 6% YoY | Payers and providers at different transformation stages; dedicated leadership roles created for both segments; large-deal ramp-ups progressing; planned provider account rationalisation may weigh on optical growth short-term. |
| CMT | ▲ 14% YoY | Seasonally soft Q3 due to holidays; growth driven by consumer tech and AI-integration solutions; pipeline well-balanced and healthy. |
| Diverse Portfolio | ▲ 21% YoY | Includes utilities and retail, mainly UK; Pastdue Credit adds large logos in utilities; retail expanding through footprint and renewal add-ons; seasonal retail strength in Q3 partly offset by Technology weakness. |
| North America | ▲ 13% YoY | Broad-based momentum across three core verticals; incubating new growth in Canada and replicating UK capabilities. |
| Europe | ▲ 2% YoY | Accelerating offshore/nearshore delivery; pipeline up ~40% over four quarters; renewed UK banking contract as primary onshore and offshore partner; three large deals won. |
| Australia | ▲ Growth | Winning additional business with existing clients; one of the largest deal wins in Q3. |
- Mortgage business stable but rate-dependent: Growth is coming from broad-basing clients and offerings on both origination and servicing sides. A refinance tailwind is expected only when 30-year mortgage rates approach 5%, given 88% of existing mortgages are below that threshold.
- Credit card late fee cap: No near-term business impact seen and not featuring in client conversations. Medium-term, banks may respond with lower credit limits and tighter underwriting if the cap pressures card unit economics.
Idnani: "This is a tweet. The President tweets a bunch of things and details of implementation, compliance requirements, et cetera are still awaited."
Healthcare: CMS Uncertainty & Strategic Bets
- CMS Medicare Advantage rate proposal: The proposal to keep rates largely unchanged adds pressure on payer margins already stressed by rising medical and utilisation costs. Management views this as a net positive tailwind, expecting more outsourcing, offshoring and demand for transformational programmes that deliver structural cost uplift.
- TeleMedik acquisition: The Puerto Rico-based pioneer, with ~3 decades of operations, strengthens end-to-end clinical and utilisation management capabilities in Medicaid, Medicare Advantage and dual-eligible segments. Its on-ground presence in Puerto Rico offers a structural cost advantage for Medicaid work that cannot move outside the US. Integration begins in Q4.
- Dedicated payer and provider leadership: Matthew Barlow (payer) and Scott Schrader (provider), each with over two decades of industry experience, were appointed to lead the two healthcare sub-segments, signalling a sharper go-to-market focus.
- Final rates still pending: Management declined to quantify the impact of the CMS proposal, noting that final rates will only be released in a few months.
Idnani: "Our view is that, this should lead to not just more outsourcing, but also more offshoring and clients looking for more transformational programs that give them a structural uplift in their cost structure. So, we think it is a net positive in terms of a tailwind."
Deal Wins, Pipeline & Strategic Logos
- 13 large deals in nine months: The tally compares to 14 in all of FY25 and nearly double FY24. Six came from new logos versus five in FY25, breaking the historical pattern of large deals almost always coming from existing clients.
- Five large deals in Q3: Wins spanned an on-demand US manufacturing marketplace (account servicing and CX), a communications/media company (customer onboarding, in-house teams), a UK-based MVNO (new logo, global operations outsourcing), a global online fashion retailer (new logo, customer operations), and a large Australian health insurer (onshore CX, member services).
- Pipeline stays above US$1 bn: Despite strong closure, the overall deal pipeline held above the US$1 bn mark. BFSI exited Q3 with one of its strongest pipelines in recent quarters; healthcare, CMT and diverse portfolio pipelines were all described as healthy. Europe’s pipeline is up ~40% over four quarters.
- Strategic logo programme delivering: 10 of 20 strategic logos added over the past four quarters have already hit the aspirational US$5 mn relationship size, a ~60% conversion rate for the 33 strategic logos added over eight quarters. A structured programme handholds and monitors these accounts for accelerated growth.
- Deal ramp schedules vary: One large deal requires implementation of a contact-centre transformation platform before ramp; others follow more linear ramps.
Acquisitions & Capital Allocation
- Pastdue Credit Solutions: Acquired for ₹220 crore (GBP 2.2 crore including GBP 0.44 crore earnouts), fully consolidated for all three months of Q3. Adds ~300+ headcount, large and new logos in the UK utility segment, and is already generating active interest from its clients to do work from Firstsource’s South Africa footprint. Profitability is in line with company averages.
- TeleMedik: Announced last month; integration begins in Q4. The Puerto Rico location is seen as a competitive advantage for healthcare clients needing US-territory-based Medicaid work.
- Cash conversion strong: DSO improved to 67 days from 69; OCF to EBITDA at 93% for Q3 and 86% for nine months; FCF to adjusted PAT at 164% for Q3 and 159% for nine months.
- Interim dividend: Board declared ₹5.5 per share.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Organic CC revenue growth | 13% to 14% range | FY26 |
| CC revenue growth incl. acquisitions | 14.5% to 15.5% range | FY26 |
| EBIT margin | 11.5% to 12% range (raised) | FY26 |
| Annual margin expansion | 50–75 bps per year toward 14–15% band | FY26–FY28 |
| Healthcare provider account rationalisation | Optical growth drag from trimming low-margin accounts | Next 2–3 quarters |
| Non-linear revenue disclosure | More detail on outcome-based commercial structures | Starting next fiscal year |
| Tax rate | Within 1% of current guided rate of 21% | Ongoing |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹2,440 cr (US$274 mn), +16.2% YoY in rupee terms, +10.2% YoY in US$ terms, +10.6% YoY in constant currency |
| Operating profit (EBIT) | ₹290 cr, +24.9% YoY |
| EBIT margin | 11.9%, +40 bps QoQ, +80 bps over last four quarters |
| Adjusted profit after tax | ₹200 cr, +26% YoY |
| Effective tax rate | 21% for Q3, 20% for nine months |
| FY26 constant currency revenue growth guidance (organic) | 13% to 14% |
| FY26 constant currency revenue growth guidance (incl. acquisitions) | 14.5% to 15.5% |
| FY26 EBIT margin guidance | 11.5% to 12%, raised from 11.25% lower end |
| Large deals won | 5 in Q3, fourth straight quarter of four or more; 13 in 9MFY26 vs 14 in all of FY25 |
| Deal pipeline | Over US$1 bn |
| Headcount | 36,689, net increase of ~690 QoQ |
| Trailing 12-month attrition | 27.4%, improved ~10 ppt over last 8 quarters |
| Offshore revenue mix | 43.4%, up ~13–14 ppt over last 9–10 quarters |
| DSO | 67 days vs 69 days in Q2 |
| OCF to EBITDA | 93% for Q3, 86% for nine months |
| FCF to adjusted PAT | 164% for Q3, 159% for nine months |
| Net debt | ₹1,170 cr as of Dec 31, 2025 vs ₹1,080 cr as of Sep 30, 2025 |
| Interim dividend | ₹5.5 per share |
| BFSI vertical constant currency revenue growth | 9% YoY, flat sequentially |
| Healthcare vertical constant currency revenue growth | 6% YoY, flat sequentially |
| CMT vertical constant currency revenue growth | 14% YoY, +2% QoQ |
| Diverse portfolio constant currency revenue growth | 21% YoY, +37% QoQ |
| North America constant currency revenue growth | 13% YoY, +1% QoQ |
| Europe constant currency revenue growth | 2% YoY, +14% QoQ |
| Clients with >US$1m revenue run-rate | 141, addition of 34 over Q3FY25 |
| One-time charge (gratuity/leave encashment provisioning) | ₹91.4 cr |
| Exceptional item (legacy investment diminution) | ₹8.8 cr |
| Tail account rationalization impact on FY26 revenue growth | ~50 bps |